# Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR

Study · id `cardio:ct-nct01761656` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01761656](<https://clinicaltrials.gov/study/NCT01761656>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01761656

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

## Technical summary

Registry record NCT01761656. Randomized; no masking; primary purpose prevention. Start 2012-12 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT01761656, source copy `cardio:ctgov-nct01761656-2013-01-08`, retrieved 2026-10-26)
- Start date: 2012-12 (registry gives no type) (ClinicalTrials.gov record NCT01761656, source copy `cardio:ctgov-nct01761656-2013-01-08`, retrieved 2026-10-26)
- Primary completion: 2013-12 (anticipated) (ClinicalTrials.gov record NCT01761656, source copy `cardio:ctgov-nct01761656-2013-01-08`, retrieved 2026-10-26)
- Completion: 2014-02 (anticipated) (ClinicalTrials.gov record NCT01761656, source copy `cardio:ctgov-nct01761656-2013-01-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01761656, source copy `cardio:ctgov-nct01761656-2013-01-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01761656-2013-01-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR
- Acronym: ARMYDA-IMR
- Condition: Stable Angina
- Condition: Unstable Angina
- Condition: Acute Non-ST-segment Elevation Myocardial Infarction
- Intervention (Drug): loading dose atorvastatin
- Intervention (Drug): conventional dose atorvastatin
- Lead sponsor: Central South University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Central South University (`cardio:org-central-south-university`)

## Provenance

Content hash: 5998cf26f59c185a4b1c64e4c92cba7d25edfd653dc02efde07baaf2bf6b52fd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
